Natco Pharma Launches Generic Carboplatin Injection in the US Market
Natco Pharma Ltd 路 Press Release 路 19 Oct 2026, 7:55 pm
Natco Pharma Launches Generic Carboplatin Injection in the US Market NATCO Pharma Limited announced on 19th Oct'26 that its US subsidiary, NATCO Pharma USA LLC, has launched Carboplatin Injection (generic Paraplatin) in the US market in manufacturing collaboration with Chennai-based Teyro Labs Pvt Ltd. The oncology product addresses a critical US market shortage and is indicated for advanced ovarian carcinoma treatment. According to industry sales data, Carboplatin Injection generated estimated annual US sales of USD 27.8 million for the 12 months ending Jun'26.
Original exchange filing (PDF)
More announcements from Natco Pharma Ltd
- Intimation of Investor Meet 路 17 Nov 2026
- Audio link of Earnings Conference Call Q2FY27 路 14 Nov 2026
- Q2 FY27 Earnings Presentation 路 13 Nov 2026
- Un audited Financial Results for the quarter and half year ended 30th September, 2026 路 13 Nov 2026
- 19th November, 2026 is the Record Date for the payment of 2nd Interim Dividend for FY 2026-27 路 13 Nov 2026
- Natco Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026 and declaration of 2nd Interim Dividend for FY 2026-27 路 13 Nov 2026
- Outcome of Board Meeting 路 13 Nov 2026
- Intimation of schedule of Concall 路 13 Nov 2026
